Aurora’s $26.5M Safari Flower Deal Boosts Revenue 10% While Trulieve Lists on NYSE
OPTH•This sector update saw Aurora complete a $26.5m Safari Flower acquisition with a 59,000-sq-ft EU-GMP facility, lifting fiscal 2026 revenue 10% to $320.6m and EBITDA 32% to $53.8m. Trulieve listed on the NYSE, ring-fencing 206 DEA-registered dispensaries, while Tilray launched its ARX medical cannabis brand in Germany.
1. Aurora Strengthens Production and Delivers Record Results
Aurora finalized the $26.5 million purchase of Safari Flower Company, adding a 59,000-square-foot EU-GMP cultivation and manufacturing facility. For fiscal year 2026, the company reported net revenue of $320.6 million, up 10%, and a record adjusted EBITDA of $53.8 million, a 32% increase, driven by global medical cannabis growth.
2. Trulieve Secures Historic NYSE Listing
Trulieve separated its federally compliant medical operations from its adult-use business and debuted on the New York Stock Exchange, ring-fencing 206 DEA-registered dispensaries. The listing grants the company broader institutional access and traditional banking services, reinforcing its national medical footprint.
3. Tilray Introduces ARX Premium German Brand
Tilray Medical Germany launched ARX, its first premium medical cannabis line cultivated entirely in Germany. Developed over two years at the Aphria RX facility in Neumünster, ARX targets consistent, high-quality therapeutic products for European patients and healthcare professionals.
4. Outlook and Canadian Reimbursement Caution
While international expansion remains the primary growth driver, Aurora warned that upcoming changes to Canadian government reimbursement rates for veterans could pressure revenue and margins in fiscal 2027, offsetting gains from markets in Germany, Poland and other international jurisdictions.
